ASX:AVHPharmaceuticals, Biotechnology & Life SciencesBiotechnology

AVITA MEDICAL CDI

$1.230
$0.020 (1.60%)
Day Range
$1.210 - $1.270
52 Week Range
$1.000 - $3.380
Volume
332.86K
Avg Volume (10D)
202.87K
Market Cap
$105.96M
Price Chart
Market Statistics
Open$1.220
Previous Close$1.250
Day High$1.270
Day Low$1.210
52 Week High$3.380
52 Week Low$1.000
Valuation
Market Cap105.96M
Shares Outstanding86.14M
Price to Book444.45
Trading Activity
Volume332.86K
Value Traded409.72K
Bid$1.230 × 6,556
Ask$1.250 × 1,300
Performance
1 Day-1.33%
5 Day5.05%
13 Week55.69%
52 Week94.76%
YTD21.21%
Technical Indicators
RSI (14)57.91
50-Day SMA$1.108
200-Day SMA$1.580
Latest News
AVITA Medical to launch RECELL GO system in US burn centres following FDA approval
Biotechnology

AVITA Medical to launch RECELL GO system in US burn centres following FDA approval

Wound care management specialist AVITA Medical (ASX: AVH) has obtained US Food and Drug Administration (FDA) approval for its RECELL GO skin restoration system. RECELL GO is a cell-harvesting device that utilises the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects. Chief executive officer Jim Corbett said […]

1 min read
Colin Hay
Colin Hay
What are the ASX stocks vulnerable to a ‘short squeeze’?
Hot Topics

What are the ASX stocks vulnerable to a ‘short squeeze’?

Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly food for short … er, thought. This month shares in online travel agent Webjet (ASX: WEB) have climbed around 10% as […]

5 min read
Tim Boreham
Tim Boreham
Avita Medical enrols first patients in studies evaluating RECELL system
Biotechnology

Avita Medical enrols first patients in studies evaluating RECELL system

Regenerative medicine company Avita Medical (ASX: AVH) has commenced what it calls a “pivotal trial” for the treatment of paediatric scald injuries, seeking to demonstrate that its RECELL treatment can safely and effectively increase the incidence of healing when compared to a standard wound dressing. The new study is Avita’s second in as many days after […]

2 min read
George Tchetvertakov
George Tchetvertakov
AVITA Medical publishes favourable study results for its RECELL System
Biotechnology

AVITA Medical publishes favourable study results for its RECELL System

Regenerative medicine company AVITA Medical (ASX: AVH) has published “favourable” results from an open-label feasibility study of its RECELL Autologous Cell Harvesting Device for the treatment of diabetic foot ulcers (DFUs). AVITA Medical has positioned itself as an innovative technology developer, intending to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA’s device […]

2 min read
George Tchetvertakov
George Tchetvertakov